Cavitation Technologies, Inc. filed a Form 10-Q with the SEC on October 27, 2026, covering the three months ended September 30, 2026, reporting a net loss of $208,000 and disclosing a new tender offer agreement with BrightFlixx Finance Luxembourg S.A. following the termination of an earlier offer.

Key Highlights

  • Net loss of $208,000 for the three months ended September 30, 2026, compared to a net loss of $258,000 in the same period a year earlier, according to the filing.
  • Zero revenue reported for the quarter ended September 30, 2026, down from $3,000 in the comparable prior-year quarter.
  • Total assets of $118,000 and total liabilities of $857,000 as of September 30, 2026, resulting in a total stockholders' deficit of $739,000.
  • Accumulated deficit reached $28,572,000 as of September 30, 2026, up from $28,364,000 at June 30, 2026.
  • 324,320,459 shares of common stock were issued and outstanding as of October 27, 2026, up from 317,220,739 at June 30, 2026.
  • EGS tender offer terminated in October 2026 after being received on August 14, 2026; a new tender offer agreement with BrightFlixx Finance Luxembourg S.A. was entered into on October 9, 2026.
  • Cash and cash equivalents totaled $94,000 at September 30, 2026, up from $17,000 at June 30, 2026, driven by $140,000 in common stock subscription proceeds and $65,000 from bridge notes payable.

Cavitation Technologies: Financial Position and Corporate Activity in Q1 FY2027

Cavitation Technologies, Inc. (OTC:CVAT), a Nevada corporation headquartered in Chatsworth, California, filed its quarterly report for the period ended September 30, 2026. The company, which originally developed and patented proprietary cavitation technology, sold that technology to Desmet Ballestra in October 2024 pursuant to a patent assignment and license back agreement, as the filing describes. The company also holds a 17% equity stake in Alchemy Beverages Inc., a privately held Delaware corporation, according to the filing.

For the three months ended September 30, 2026, the company reported no revenue, compared to $3,000 in the same period of 2025. General and administrative expenses were $165,000, down from $245,000 in the prior-year quarter. Interest and other expense, net, totaled $40,000, and a change in fair value of derivative liability contributed an additional $3,000 loss, bringing the total net loss to $208,000 for the quarter. Net cash used in operating activities was $128,000, while financing activities provided $205,000, consisting of $140,000 from common stock subscriptions and $65,000 from bridge notes payable.

On August 14, 2026, the company received a tender offer from European Guarantee Services S.a.r.l. (EGS), under which EGS agreed to seek to acquire all outstanding shares for $35 million in cash, less certain indebtedness and accrued liabilities, according to the filing. That offer was terminated in October 2026. On October 9, 2026, the company and Alchemy Beverages Inc. entered into definitive tender offer agreements with BrightFlixx Finance Luxembourg S.A., with one agreement relating to the company and a separate agreement relating to Alchemy Beverages Inc., the filing states. The company is classified as a smaller reporting company and non-accelerated filer.

What Was Disclosed

Cavitation Technologies filed its quarterly report for the three months ended September 30, 2026, disclosing a net loss of $208,000, zero revenue, a stockholders' deficit of $739,000, the termination of an earlier tender offer, and the signing of a new tender offer agreement with BrightFlixx Finance Luxembourg S.A. on October 9, 2026.